Epsilon Healthcare Ltd (epn) Logo

Epsilon Healthcare Ltd (EPN)

___:___ · AUD

EPN Chart

EPN's Principal Activity is the the Group plans to be a worldwide manufacturer and distributor of hydroponics equipment, materials and nutrients; and leader in the development and delivery of medicinal cannabis.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume (4w avg)
Day Range -
Prev Close
Last Trade


1 Week
1 Month
2021 YTD
1 Year
vs Sector (1yr) -
vs ASX 200 (1yr) -75.50%


Market Capitalisation
ASX Rank 1,570 of 2,298
Sector Rank

Key Information

Shares Issued
Sector Healthcare
Similar Companies -
EPS -$0.069
DPS $0.00
NTA per share $0.10

Broker Consensus

EPN is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.


Date Heading Pages File Size Time

Company Overview

Epsilon Healthcare Limited (EPN, formerly THC Global Group Limited) is a diversified global cannabis company with primary operations in Australia and Canada. EPN owns and operates end to end commercial medicinal cannabis production facilities under Australia's cannabis regulations. EPN also owns and operates a turnkey cultivation solutions provider, including a hydroponics equipment and supplies wholesaler and retailer servicing the rapidly expanding cannabis sectors in North America and Europe.

Incorporation Details

No incorporation details available.

Corporate Details

Head Office Sydney NSW 2000
Website www.epsilonhealthcare.com.au
Registry Computershare
Auditor RSM Australia Partners
Date Listed 4 May 2017

Upcoming Calendar (Forecasted)

Date Event
30/08/2021 Report (Interim)
25/02/2022 Report (Prelim)
29/04/2022 Report (Annual)

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
No dividends paid.

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors & Management

Name Title Since Bio
Ms Louisa Ho Company Secretary Jun 2021
Mr Jarrod Travers White Chief Executive Officer May 2020
Mr Sonny Didugu Joint Company Secretary,Chief Operating Officer May 2020
Mr Lou Anthony Cattelan Non-Executive Director Mar 2018 Director Bio icon

Mr Lou Anthony Cattelan

Non-Executive Director

Mr Cattelan has experience in the pharmaceutical, nutraceutical, complementary healthcare, and allied health industry sectors with over 30 years experience across a range of operational and strategic areas including, quality assurance, supply chain management, new product development, TGA and FDA regulatory compliance, sales and marketing, business development, and special projects. He has sat on the Consumer Healthcare Products Australia Committee for Complementary Medicines as a key liaison between TGA and industry stakeholders. He has now retired as Head of Sales and Marketing of Contract Pharmaceutical Services of Australia (CPSA). In this role over the past 19 years, he has consulted all Pharma companies including Pfizer, MSD, Mylan and GSK to take innovative concepts through to compliant finished products. He has also worked in senior hands-on positions with Ella Bache, Milpharma, Sunspot Products, Bayer Pharma and Blackmores. He is a member of Risk Committee.

Mr Steven Xiaobo XU Non-Executive Director Jan 2018 Director Bio icon

Mr Steven Xiaobo XU

Non-Executive Director

Mr Xu is the Managing Director of Une-Innovation Consulting Australia Pty Ltd and Founding Partner of INP Capital Inc which manages a series of venture capital funds. The venture capital funds invest in companies specialised in Medical/Healthcare, AI, Fintech and Industrial technology and Medical Cannabis across Australia, New Zealand, North America and Israel. He has over 15 years experience working at PricewaterhouseCoopers and listed companies in Australia and China. He specialises in financing, IPO and M&A activities in a range of sectors. He is the Chairman of the Strategy and Management Committee (from 4 June 2019) and Risk Committee.

Mr Alan Preston Beasley Non-Executive Director,Non-Executive Deputy Chairman Aug 2016 Director Bio icon

Mr Alan Preston Beasley

Non-Executive Director,Non-Executive Deputy Chairman

Mr Beasley has worked in the Investment Banking and Investment Management industries for over 30 years with Bankers Trust Australia, Goldman Sachs Asset Management, and BNP Paribas Asset Management Ltd. The last two positions as Managing Director and Australian Country Head. He is a director and former director of several listed and unlisted public and private companies including two public charities. He has experience in assisting to bring innovative and new technology companies to market, especially in the Health and Life Sciences sectors. He is the Chairman of Risk Committee and a member of Strategy and Management Committee (from 4 June 2019).

Director Transactions

EPN directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
07/09/20 Gary Radcliff Buy +44,900 $0.24 $10,776 On-market trade

Director Interests

The current holdings of EPN directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Lou Cattelan 31/12/2020 N/A 327,803 N/A N/A
Alan Beasley 31/12/2020 N/A 880,000 N/A N/A
Steven XU 31/12/2020 243,334 1,587,302 N/A N/A

Shareholder Info

Top 20 Shareholders About the Data

Data supplied by Morningstar and accurate on Apr 26, 2021.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
Barcoo Holdings Pty Ltd (Wyan Family Investments) 3,528,046 1.85%
BNP Paribas Nominees Pty Ltd (Ib Au Noms Retailclient Drp) 3,304,319 1.73%
Meta Growth Corp 2,942,489 1.54%
Health360 Investment Management Inc 2,698,334 1.42%
Barcoo Holdings Pty Ltd (Maple Ventures) 2,438,341 1.28%
Marcus Kelly Property Developments Pty Ltd 2,356,926 1.24%
Mcann Investments Pty Ltd 2,000,000 1.05%
Mr George Daaboul 2,000,000 1.05%
Citicorp Nominees Pty Limited 1,990,856 1.05%
Mrs Katja Gordon 1,865,000 0.98%
Agri Fibre Industries Pty Ltd 1,777,512 0.93%
Une-Innovation Consulting Australia Pty Ltd 1,587,302 0.83%
Pears Daisley Pty Ltd (Daisley Pears A/C) 1,500,000 0.79%
Mr Nicholas Charles Deverell Pownall 1,450,000 0.76%
Sawfam Pty Ltd (Sawyer Super Fund A/C) 1,409,751 0.74%
Bell Pro Investments Pty Limited 1,205,273 0.63%
Madonna Andrews (Andrews Family A/C) 1,023,810 0.54%
Mr Brian Thomas Clayton & Mrs Janet Clayton 1,000,000 0.53%
Superhero Nominees Pty Ltd 962,124 0.51%
HSBC Custody Nominees (Australia) Limited 925,800 0.49%

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 1,216 4,409 1,407 2,153 286 9,471

Substantial Shareholders

No Substantial Shareholders for EPN in our database.

Shareholders Buying

12 month transaction history compiled from ASX announcements.

No buy transactions reported by Substantial Shareholders in the past 12 months.

Shareholders Selling

12 month transaction history compiled from ASX announcements.

No sell transactions reported by Substantial Shareholders in the past 12 months.

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
No Financial Year End data available
Page Icon
EPN Historical Price Data (CSV)
Up to 20 years of EOD share price history
Lock Icon
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.